HIKAL LTD. - 524735 - Closure of Trading Window
Intimation of closure of Trading Window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201526-06-2024
26-06-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation under Regulation 30 of SEBI Listing Regulations - Reminder letters to shareholders regarding unclaimed Final Dividend 2016-17 and subsequent newspaper publication06-06-2024
HIKAL LTD. - 524735 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for financial year ended March 31, 2024.30-05-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation of officials of the Company in the investors Conference organised by B and K Securities India.24-05-2024
HIKAL LTD. - 524735 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Voting Results of Postal Ballot pursuant to Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524-05-2024
HIKAL LTD. - 524735 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Voting results of Postal Ballot through remote e-voting and Scrutinizer''s Report thereon24-05-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of earnings call held on May 9, 2024 for quarter and financial year ended March 31, 202415-05-2024
HIKAL LTD. - 524735 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Submission of audio recording of earnings conference call for the period ended Q4 FY2409-05-2024
Hikal Results Earnings Call for Q4FY24
Conference Call with Hikal Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.09-05-2024
FY24 Annual Result Announced for Hikal Ltd.
Pharmaceuticals company Hikal announced FY24 results: Financial Highlights: Revenue of Rs 1,785 crore EBITDA stood at Rs 267 crore PAT stood at Rs 70 crores Recommended a final dividend of Rs 0.60 per share (30% of FV); Total dividend for FY24 stands at Rs 1.2 per share (60% of FV) Hikal’s long term credit rating is maintained at A+ by ICRA Commenting on the results, Jai Hiremath, Executive Chairman, Hikal said, “For the FY24, we achieved revenues of Rs 1,785 Crores as compared to Rs 2,023 Crores last year. FY24 was marred with several global macroeconomic pressures and depressed market conditions for the global chemical sector on account of inventory build up and overcapacity across the sector resulting in intense price competition from China predominantly in the Crop Protection market. Our Board of Directors has recommended a final dividend of Rs 0.60 per share (30%). Along with an interim dividend of Rs 0.60 per share (30%) declared in February 2024, the total dividend for FY24 stands at Rs 1.20 per share (60% of FV). For Q4FY24, our pharmaceutical business reported revenue growth of 26% to Rs 338 Cr and EBIT growth of 191% to Rs 54 Cr, on QoQ basis. In the API segment, we witnessed increased volume off-take based on higher demand from existing customers and from newer geographies. This coupled with stabilized raw material prices have supported us in maintaining our margin profile. In our CDMO segment we have received several RFP’s from both emerging pharma and global innovators, with several products progressing through the development stages. We have a healthy pipeline of projects in the early to mid-phase that is encouraging. During FY24, our API facility in Panoli, Gujarat, was audited by the US FDA, and the audit was concluded with ‘Zero’ 483 observations as a testament of our commitment to high standards of regulatory compliance. For Q4FY24, our crop protection business reported revenue of Rs 177 Cr and EBIT of Rs 14 Cr. Despite proactive cost improvement initiatives, the global crop protection industry continues to face significant headwinds, including subdued global demand due to inventory in the channel pipeline and intense price erosion from competitors primarily China as a result of large capacity which are under-utilized. We expect the market to stabilize post the end of this financial year and recovery to begin thereafter. In our animal health business, advancements in developing a portfolio of products under a long-term agreement with an innovator animal health company are proceeding well. During the third quarter, our new multipurpose animal health facility was commissioned at Panoli, Gujarat. Validation of several products is underway, and it is scheduled to be completed in the upcoming quarters. These validation batches mark the initial phase toward product registration and subsequent commercialization. Under our strategic transformation initiative - Pinnacle, we have taken substantial strides toward sustaining growth across our various businesses. We have gained momentum in supply chain derisking, developing differentiated capabilities, the acquisition of new customers and the building of a distinctive technology platform. As we navigate through the next stage of our strategic plan, our focus is directed more towards the front-end capitalizing on the opportunities to build a healthy pipeline for our businesses. Despite the current challenging global conditions, we anticipate a favorable shift in market dynamics over the mid to long term, and we remain focused in our strategy to deliver profitable, and sustainable growth across our businesses.” Result PDF09-05-2024